Tobin Schilke has sold stock and made no open-market buys since Jun 2017

Tobin “Toby” Schilke is the Chief Financial Officer of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), appointed effective February 28, 2025.( Age 50, he brings over 25 years of experience in biopharmaceutical finance, operations, and commercialization, having previously served as CFO at Revance Therapeutics (2018–2025), where he oversaw finance, investor relations, IT, and technical operations for a 650-employee public company, supporting two product launches, executing over $1.5 billion in financings, and achieving more than $700 million in cumulative revenue.(

Prior to Revance, Schilke was CFO at Achaogen (2016–2018), building financial planning, accounting, procurement, IT, and facilities functions to enable the company's first product approval and launch.( Earlier, he spent over a decade at Roche/Genentech in progressively senior roles in corporate development, commercial finance, marketing, and global operations.( He holds a B.S. in chemical engineering from Lafayette College, an M.S. in chemical engineering from UC Berkeley, and an MBA from Cornell University.(

Written by Perplexity from public sources.